Efficacy of rapamycin in scleroderma: a case study.

Efficacy of rapamycin in scleroderma: a case study.

Item
http://www.wikidata.org/entity/Q37250880
Immunotherapy of systemic sclerosismTOR: a potential therapeutic target in osteoarthritis?Dual mTOR Inhibition Is Required to Prevent TGF-β-Mediated Fibrosis: Implications for SclerodermaNew molecular medicine-based scar management strategiesReduction of intraarticular adhesion of knee by local application of rapamycin in rabbits via inhibition of fibroblast proliferation and collagen synthesis.Fibroblast autophagy in fibrotic disorders.Visible effects of rapamycin (sirolimus) on human skin explants in vitro.Sirtuin1 Protects against Systemic Sclerosis-related Pulmonary Fibrosis by Decreasing Proinflammatory and Profibrotic Processes.The mammalian target of rapamycin inhibitor everolimus suppresses proliferation, metabolic activity and collagen synthesis of human fibroblasts in vitro and exerts antifibrogenic effects in vivo.Differential Expression of Hedgehog and Snail in Cutaneous Fibrosing Disorders: Implications for Targeted Inhibition.
P2860

Efficacy of rapamycin in scleroderma: a case study.

Item
http://www.wikidata.org/entity/Q37250880
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy of rapamycin in scleroderma: a case study.
@en
Efficacy of rapamycin in scleroderma: a case study.
@nl
type
label
Efficacy of rapamycin in scleroderma: a case study.
@en
Efficacy of rapamycin in scleroderma: a case study.
@nl
prefLabel
Efficacy of rapamycin in scleroderma: a case study.
@en
Efficacy of rapamycin in scleroderma: a case study.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P932
P356
P1433
P1476
Efficacy of rapamycin in scleroderma: a case study.
@en
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P932